Phase2/3 Study of OTS102 in Combination With Gemcitabine in Patients With Unresectable Advanced Pancreatic Cancer and Recurrent Pancreatic Cancer(PEGASUS-PC Study).

Trial Profile

Phase2/3 Study of OTS102 in Combination With Gemcitabine in Patients With Unresectable Advanced Pancreatic Cancer and Recurrent Pancreatic Cancer(PEGASUS-PC Study).

Completed
Phase of Trial: Phase II/III

Latest Information Update: 09 Dec 2014

At a glance

  • Drugs Elpamotide (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Expanded access; Therapeutic Use
  • Acronyms PEGASUS-PC
  • Sponsors OncoTherapy Science
  • Most Recent Events

    • 26 Jan 2013 Results presented at the 2013 Gastrointestinal Cancers Symposium.
    • 26 Jan 2013 Primary endpoint 'Overall-survival-duration' has not been met.
    • 12 Jun 2012 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan. (Parent trial: UMIN000001664)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top